Skip to main content
  • BIOMAG-I Clinical Trial Reaches Primary Endpoint at Six Month for Unique Next Generation Resorbable Magnesium Scaffold

    The Multi-Center First-in-Men Study Evaluates the Safety and Performance of the Next Generation of BIOTRONIK’s Resorbable Magnesium Scaffold (RMS)

    n the “TCT Innovation” session Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the new BIOMAG-I study results at the Transcatheter Cardiovascular Therapeutics (TCT) 2022. The multi-center study assesses the angiographic, clinical and safety performance of DREAMS 3G in patients with de novo coronary artery lesions,  of BIOTRONIK’s next-generation resorbable magnesium scaffold (RMS). The data will be submitted to The Lancet. 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details